These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 38365072)

  • 1. Out-of-pocket prescription drug costs for adults with cardiovascular risk factors under Amazon's direct-to-consumer pharmacy service.
    Oddleifson DA; Zheng Z; Wadhera RK
    Am Heart J; 2024 May; 271():20-27. PubMed ID: 38365072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Branded Prescription Drug Rebate Size and Patient Out-of-Pocket Costs in a Nationally Representative Sample, 2007-2018.
    Yeung K; Dusetzina SB; Basu A
    JAMA Netw Open; 2021 Jun; 4(6):e2113393. PubMed ID: 34125219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of Low-Cost Generic Program Use in a Nationally Representative Cohort of Privately Insured Adults.
    Pauly NJ; Brown JD
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1162-70. PubMed ID: 26679965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Out-of-Pocket Drug Costs for Medicare Beneficiaries With Cardiovascular Risk Factors Under the Inflation Reduction Act.
    Narasimmaraj PR; Oseran A; Tale A; Xu J; Essien UR; Kazi DS; Yeh RW; Wadhera RK
    J Am Coll Cardiol; 2023 Apr; 81(15):1491-1501. PubMed ID: 37045519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of a transition to more restrictive drug formulary on therapy discontinuation and medication adherence.
    Shirneshan E; Kyrychenko P; Matlin OS; Avila JP; Brennan TA; Shrank WH
    J Clin Pharm Ther; 2016 Feb; 41(1):64-9. PubMed ID: 26778812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-Cost Generic Program Use by Medicare Beneficiaries: Implications for Medication Exposure Misclassification in Administrative Claims Data.
    Pauly NJ; Talbert JC; Brown J
    J Manag Care Spec Pharm; 2016 Jun; 22(6):741-51. PubMed ID: 27231801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in Use and Expenditures for Brand-name Statins After Introduction of Generic Statins in the US, 2002-2018.
    Lin SY; Baumann K; Zhou C; Zhou W; Cuellar AE; Xue H
    JAMA Netw Open; 2021 Nov; 4(11):e2135371. PubMed ID: 34807258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D.
    Dusetzina SB; Sarpatwari A; Carrier MA; Hansen RA; Keating NL; Huskamp HA
    JAMA Intern Med; 2021 Dec; 181(12):1605-1611. PubMed ID: 34661600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer History, Health Insurance Coverage, and Cost-Related Medication Nonadherence and Medication Cost-Coping Strategies in the United States.
    Zhao J; Zheng Z; Han X; Davidoff AJ; Banegas MP; Rai A; Jemal A; Yabroff KR
    Value Health; 2019 Jul; 22(7):762-767. PubMed ID: 31277821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and predictors of utilization of community pharmacy generic drug discount programs.
    Gatwood J; Tungol A; Truong C; Kucukarslan SN; Erickson SR
    J Manag Care Pharm; 2011; 17(6):449-55. PubMed ID: 21787030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997-2000.
    Haas JS; Phillips KA; Gerstenberger EP; Seger AC
    Ann Intern Med; 2005 Jun; 142(11):891-7. PubMed ID: 15941695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Patient Reimbursement Timing and Patient Out-of-Pocket Expenses on Medication Adherence in Patients Covered by Private Drug Insurance Plans.
    Després F; Forget A; Kettani FZ; Blais L
    J Manag Care Spec Pharm; 2016 May; 22(5):539-47. PubMed ID: 27123915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Online Tools to Decrease Out-of-Pocket Prescription Costs for Patients: A Practical Guide for Urologists.
    Pockros B; Cortese BD; Michel K; Ellis TA; Talwar R
    Urol Pract; 2024 May; 11(3):454-460. PubMed ID: 38640418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prescription drug costs and the generic dispensing ratio.
    Liberman JN; Roebuck MC
    J Manag Care Pharm; 2010 Sep; 16(7):502-6. PubMed ID: 20726679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ophthalmic Medication Expenditures and Out-of-Pocket Spending: An Analysis of United States Prescriptions from 2007 through 2016.
    Chen EM; Kombo N; Teng CC; Mruthyunjaya P; Nwanyanwu K; Parikh R
    Ophthalmology; 2020 Oct; 127(10):1292-1302. PubMed ID: 32359935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost reduction strategies used by elderly patients with chronic obstructive pulmonary disease to cope with a generic-only pharmacy benefit.
    Spence MM; Hui R; Chan J
    J Manag Care Pharm; 2006 Jun; 12(5):377-82. PubMed ID: 16792444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Save green, go generic: be prepared to answer the $4 question.
    Hansen D
    S D Med; 2009 Nov; 62(11):436-7. PubMed ID: 20128174
    [No Abstract]   [Full Text] [Related]  

  • 18. Brand Medications and Medicare Part D: How Eye Care Providers' Prescribing Patterns Influence Costs.
    Newman-Casey PA; Woodward MA; Niziol LM; Lee PP; De Lott LB
    Ophthalmology; 2018 Mar; 125(3):332-339. PubMed ID: 28625684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Related Medication Nonadherence Among Older Adults: Findings From a Nationally Representative Sample.
    Chung GC; Marottoli RA; Cooney LM; Rhee TG
    J Am Geriatr Soc; 2019 Dec; 67(12):2463-2473. PubMed ID: 31437309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of brand drug discount cards on private insurer, government and patient expenditures.
    Law MR; Chan FKI; Harrison M; Worthington HC
    CMAJ; 2019 Nov; 191(45):E1237-E1241. PubMed ID: 31712357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.